课题基金 / 基金详情

Development of a new drug for heart failure

Development of a new drug for heart failure
开发治疗心力衰竭的新药
批准号:
14370032
负责人:
INUI Makoto
金额:
$8.7万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

INUI Makoto的其他基金

相似基金

相关文献

中文摘要
翻译
心肌的收缩和舒张受细胞内钙离子(Ca)的调节。其中,心肌肌浆网(SR)的钙泵(SERCA)和钙释放通道在上述过程中起着关键作用。心肌的SERCA由另一种SR蛋白受磷蛋白调节,该蛋白抑制SERCA的活性。受磷蛋白的抑制作用的消除促进了心肌的松弛并增加了收缩性。已经显示去除受磷蛋白抑制改善心力衰竭。为了开发治疗心力衰竭的新药,我们研究了SERCA和受磷蛋白之间的分子相互作用以及调节这种相互作用的因素。以下是我们的结果的总结。1.筛选靶向SERCA-受磷蛋白系统的药物的方法的开发我们使用每个蛋白质的胞质区域的融合蛋白重建SERCA和受磷蛋白之间的分子相互作用。优化条件, ...更多信息 在384孔板上,我们成功地开发了一种筛选靶向SERCA-受磷蛋白系统的药物的方法2.寻找调节受磷蛋白寡聚体结构的因素由于受磷蛋白只有单体形式而不是五聚体形式抑制SERCA,因此了解这两种形式之间的动态平衡是很重要的。增加单体形式解离寡聚体的因素可以潜在地影响心肌的收缩性。在八个磷脂检查,磷脂酸是一个有效的诱导剂的五聚体解离,而其他磷脂表现出五聚体稳定活性。溶血磷脂酰胆碱、溶血磷脂酰乙醇胺和磷脂酰甘油是五聚体的高效稳定剂。因此,SR膜中的磷脂是这种蛋白质的单体和五聚体形式之间平衡的重要决定因素。我们的研究结果表明,直接或间接通过磷脂酶D增加受磷蛋白五聚体形式的药物可能改善心肌功能。少
英文摘要
Contraction and relaxation of heart muscle is regulated by intracellular calcium ions (Ca). Especially, Ca pumps (SERCA) and Ca release channels of cardiac sarcoplasmic reticulum (SR) play pivotal roles in these processes. SERCA of heart muscle is modulated by another SR protein phospholamban which inhibits the activity of SERCA. Removal of the inhibition by phospholamban facilitates relaxation of heart muscle and increases the contractility. It has been shown that removal of phospholamban inhibition improves heart failure. In order to develop a new drug for heart failure, we investigated the molecular interaction between SERCA and phospholamban and factors that modulate the interaction. The followings are the summary of our results.1.Development of a screening method for a drug which targets the SERCA-phospholamban systemWe reconstituted the molecular interaction between SERCA and phospholamban using fusion proteins of cytoplasmic regions of each protein. Optimizing the conditions for … More a 384-well plate, we succeeded in development of a screen method for a drag which targets the SERCA-phospholamban system2.Searching for factors which modulate oligomeric structure of phospholambanSince only the monomeric form, not a pentameric form, of phospholamban inhibits SERCA, it is important to gain insight into the dynamic equilibrium between these two forms. Factors that increase the monomeric form dissociating the oligomer can potentially affect the contractility of heart muscle. Among the eight phospholipids examined, phosphatidic acid was an effective inducer of pentamer dissociation, whereas the other phospholipids exhibited pentamer-stabilizing activity. Lysophosphatidylcholine, lysophosphatidylethanolamine, and phosphatidylglycerol were highly effective stabilizers of the pentamer. The phospholipids in the SR membrane are thus important determinants of the equilibrium between the monomeric and pentameric forms of this protein. Our results suggest that a drug that directly or indirectry through phospholipase D increases the pentameric form of phospholamban potentially improves heart muscle function. Less
期刊论文(46)
专著(0)
科研奖励(0)
会议论文
Yanai R.: "Mitogenic and anti apoptotic effects of various growth factors on human corneal fibroblasts"Invest.Ophthalmol.Vis.Sci.. 43. 2212-2216 (2002)
Yanai R.:“各种生长因子对人角膜成纤维细胞的促有丝分裂和抗凋亡作用”Invest.Ophasemol.Vis.Sci.. 43. 2212-2216 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
PSD-95 eliminates src induced potentiation of NRI/NR2A-subtype NMDA receptor channels and reduces high-affinity zinc inhibition.
PSD-95 消除 src 诱导的 NRI/NR2A 亚型 NMDA 受体通道增强作用,并减少高亲和力锌抑制。
DOI: --
发表时间: 2002
期刊: Journal of Neurochemistry 81
影响因子: --
作者: [Yasue Yamada]
通讯作者: Yasue Yamada
Method of screening remedy for heart failure
心力衰竭治疗的筛选方法
DOI: --
发表时间: 2003
期刊:
影响因子: --
作者: []
通讯作者:
Naoyuki Yamada: "Role of the C domain of IGFs in the synergistic promotion with a substance P-derived peptide of rabbit corneal epithelial wound healing"Invest.Ophthalmol.Vis.Sic.. (in press). (2004)
Naoyuki Yamada:“IGF 的 C 结构域在与 P 物质衍生肽协同促进兔角膜上皮伤口愈合中的作用”Invest.Ophasemol.Vis.Sic..(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 19 条
    Ultrastructural analysis of calcium transport system of cardiac sarcoplasmic reticulum for drug development
    • 批准号:
      17H04033
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.48万
    • 财政年份:
      2017
    • 负责人:
      INUI Makoto
    • 依托单位:
    Elucidation of the molecular mechanisms by a cyclic peptide, SEK-1005 promotes skin wound healing
    • 批准号:
      16K15203
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.25万
    • 财政年份:
      2016
    • 负责人:
      INUI Makoto
    • 依托单位:
    Analysis of IGF-1 receptor-independent signaling from IGF-1 and its application for drug development
    • 批准号:
      25670128
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2013
    • 负责人:
      INUI Makoto
    • 依托单位:
    Development of a new drug for heart failure targeting phospholamban
    • 批准号:
      25293062
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2013
    • 负责人:
      INUI Makoto
    • 依托单位:
    国内基金
    海外基金
    RBM3/STAT3/HO-1轴调控SERCA2a在血糖波动加剧心房颤
    • 批准号:
      82600650
    • 项目类别:
      青年科学基金项目(C类)
    • 资助金额:
      30.00万元
    • 批准年份:
      2026
    • 负责人:
      刘欢欢
    • 依托单位:
    SERCA2介导的内质网-线粒体钙稳态在AKI中的机制与干预研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      彭张哲
    • 依托单位:
    SERCA2通过PARK7-ROS抑制铁死亡减轻肾纤维化的机制研究
    Sorbs2调控SERCA2a在心肌梗死后室性心律失常发生中的作用及机制研究
    • 批准号:
      82670417
    • 项目类别:
      面上项目
    • 资助金额:
      47.00万元
    • 批准年份:
      2026
    • 负责人:
      钱玲玲
    • 依托单位: